BCL2 and prostate carcinoma: Moreover, in prostate cancer, miR-34a is markedly underexpressed in cancer stem cell (CD44+) subpopulations; enforced re-expression of miR-34a significantly inhibits tumor regeneration and metastasis, likely through targeting of stemness and survival regulators such as CD44, NOTCH, MYC, and BCL-2 [33].